Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Author: zoltanfulop
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Cyclo Therapeutics reports international patent application for treating Alzheimer’s
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
Cyclodextrins have not been popular excipients for nasal or pulmonary drug delivery so far. This can change soon, with the
Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
Cyclodextrins without holes are reality
The smallest possible cyclodextrins were synthesized by Japanese scientists. They are the first new small cyclodextrins since 1994 when the synthesis of the five membered cyclodextrin was described.